DHR
205.80
-0.70 (-0.34%)
EUR · F
52-week range
137.27
207.04
Trading at 98% of the 52-week range
Market Cap
145.17B
P/E Ratio
41.38
Forward P/E
23.87
Book Value
66.82
Div. Yield
0.71%
% Institutions
84.30%
% Insiders
10.96%

1 Year

+16.9%

3 Year

+4.9%

10 Year

+255.9%
Description

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Actions

Open action list

Add an action for DAP.F, or sign in to see your action list.

Company Information

▼
Company Name
Danaher Corporation
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
F
Currency: EUR
Full Time Employees: 58,000
Phone: 202 828 0850
Website: danaher.com
Fiscal Year End: December
Description:

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Address:

2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701

People

▼

Directors & Officers

Name Title Year Born
Mr. Steven M. Rales Co-Founder & Chairman 1951
Ms. Julie Sawyer Montgomery President, CEO & Director 1972
Mr. Mitchell P. Rales Co-Founder & Director 1957
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Senior VP & Chief Science Officer 1962
Mr. Matthew R. McGrew Executive Vice President 1972
Mr. Rainer M. Blair Senior Advisor 1964
Mr. Christopher Paul Riley Executive VP of Biotechnology Group & CEO of Cytiva 1974
Mr. Matthew E. Gugino C.F.A., CPA Executive VP & CFO 1983
Mr. Christopher M. Bouda VP & Chief Accounting Officer NA
Ms. Rachel Marie Vatnsdal Olson Vice President of Investor Relations NA

Financial Highlights

▼
Market Cap: $145.17B
EBITDA: $8.03B
P/E Ratio: $41.38
PEG Ratio: $1.33
Book Value: $66.82
Dividend/Share: $1.44
Dividend Yield: 0.71%
Earnings/Share: $4.99
Profit Margin: 15.95%
Operating Margin: 19.78%
ROA (TTM): 3.95%
ROE (TTM): 7.61%
Revenue (TTM): $25.11B
Revenue/Share (TTM): $35.47
Earnings Growth (YOY): 59.70%
Revenue Growth (YOY): 5.50%

Valuation Metrics

Enterprise Value: $155.46B
Trailing P/E: 41.38
Forward P/E: 23.87

Shares Statistics

Shares Outstanding: 702.99M
Shares Float: 625.85M
% Insiders: 10.96%
% Institutions: 84.30%

Stock Price History

▼
Open price histogram

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$24.57B
Cost of Goods Sold
adjust
$-10.05B
Gross Profit
subtotal
$14.52B
SG&A
adjust
$-8.24B
R&D
adjust
$-1.60B
Other Operating Expense
adjust
$-10.05B
Operating Income
subtotal
$4.69B
Other / Non-Operating Items
adjust
$-1.08B
Net Income
subtotal
$3.61B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about DAP.F!